nyse stocks


(Source: Google Images)

If data is the new oil, then semiconductors are the new rigs. Back in 2000s, millions of us were users of Yahoo (NASDAQ:YHOO), and in 2017, billions of us are using Google (NASDAQ:GOOG) (NASDAQ:GOOGL) and Facebook (NASDAQ:FB). What would trillions of devices use in 2035 is anybody’s guess. But one thing is certain that whatever data those devices consume, it will be processed through some kind of a semiconductor component. And there is a very high probability that a lot of that data would be processed through chips made by Taiwan Semiconductor Manufacturing Company (NYSE:TSM) (TSMC), as it is already a force to reckon with in the industry.

nyse stocks: Las Vegas Sands Corp.(LVS)


Advisors’ Opinion:

  • [By Wayne Duggan]

    According to Deutsche Bank analyst Carlo Santarelli, news that Las Vegas Sands Corp. (NYSE: LVS) may be selling its Sands Bethlehem resort to MGM Resorts International (NYSE: MGM) could be a win-win-win for Sands, MGM and MGM Growth Properties LLC (NYSE: MGP).

  • [By Ben Levisohn]

    Las Vegas Sands (LVS) has declined 1.1% to $58.60 despite beating earnings forecasts.

    O’Reilly Automotive (ORLY) has fallen 2.7% to $257.99 after missing earnings forecasts and lowering full-year guidance.

  • [By Wayne Duggan]

    The firm has a Market-Perform rating on the China unit of Las Vegas Sands Corp. (NYSE: LVS).

    All four stocks are up between 3.8 and 11.2 percent in the past month.

  • [By Travis Hoium]

    But Las Vegas Sands Corp. (NYSE:LVS) may not have had as strong a quarter as competitors like Melco Crown Entertainment Ltd (NASDAQ:MPEL) and Wynn Resorts, Limited (NASDAQ:WYNN). We’ll have to wait until the latter two report earnings to see how market share is trending, but Las Vegas Sands left a lot to be desired from a growth perspective.

  • [By WWW.THESTREET.COM]

    Cramer recalled how, in 2009, colleague Dan Fitzpatrick correctly identified Las Vegas Sands (LVS) as it broke out of its $10 a share funk and soared to $48, almost in a straight line. This technical move was brought on by Sands’ red-hot properties in Macau.

  • [By Rich Duprey]

    The big casinos certainly want to spend big. Las Vegas Sands (NYSE:LVS) says a new integrated resort in Japan will cost anywhere from $6 billion to $10 billion, two to three times more than it spent on building its brand new French-themed Parisian resort in Macau. MGM Resorts (NYSE:MGM) says it, too, could spend $10 billion for a new casino in Japan, quadruple the cost of its MGM Cotai that’s scheduled to open later this year. Wynn Resorts (NASDAQ:WYNN) hasn’t put a price tag on it yet, though it spent over $4 billion to open the Palace in Macau last August, but CEO Steve Wynn says the opportunity is “thoroughly delicious.”

nyse stocks: U.S. Geothermal Inc.(HTM)


Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap geothermal stock U.S. Geothermal Inc (NYSEMKT: HTM) is scheduled for after the market closes on Thursday (March 9th). In early February, U.S. Geothermalprovided an update on its development and expansion projects with the CEO commenting:

nyse stocks: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

nyse stocks: Cerner Corporation(CERN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Cerner (CERN) tumbled to the bottom of the S&P 500 today after meetings earnings forecasts but offering below-consensus guidance.

    Agence France-Presse/Getty Images

    Cerner dropped 4.4% to $51.50 today, while the S&P 500 rose 0.4% to 2,316.10.

    SunTrust Robinson Humphrey’s Sandy Draper and team contend that “most of the bad news is already priced in.” They explain:

    Although we expect this news to weigh on the stock…we think the market has remained cautious on CERN shares heading into the 4Q16 print given the uneven execution throughout 2016 and the post-election regulatory uncertainty that has broadly weighed on the HCIT space as a whole. We observe that CERN shares closed about 3% below the level they traded at this time last year, while the S&P was up over 21% in that time. The muted 12-month performance in the stock suggests the market rightly anticipated unattractive year-end results and 2017 guidance, which suggests to us that downside to CERN shares should be limited.


    Cerner’s market capitalization fell to $17.5 billion today from $18.3 billion yesterday.

    Barron’s Vito Racanelli recommended shares of Cerner on March 16, 2016, when the stock traded at $51.46.

  • [By Ben Levisohn]

    Cerner (CERN) soared to the top of the S&P 500 today after thehealth care information technology company reported better-than-expected earnings and revenue.

    Getty Images

    Cernergained 7.8% to $64.75 at 5:03 p.m. today, while the S&P 500 declined 0.2% to 2,384.20.


    Canaccord Genuity’s Richard Close and Brian Hoffman contend Cerner may be “rediscovered its mojo.” They explain:

    We reiterate our BUY rating and raise our PT to $66 (was $59) as the company finally
    appears to have provided quarterly and annual targets that it can meet. Possibly more important, analyst expectations sit near the mid-point of guidance, portending upside potential. The outlook appears solid as the company (1) rebuilds a track record of delivering on expectations, (2) reaffirmed confidence in 2017 bookings growth, and (3) has a strengthened pipeline for ITWorks and revenue cycle. CERN may have rediscovered its mojo.


    Cerner’s market capitalization rose to $21.4 billion today from $19.8 billion yesterday.

nyse stocks: iShares Core S&P 500 (IVV)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of SWISS RE LTD’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SWISS+RE+LTD

    These are the top 5 holdings of SWISS RE LTDiShares Core S&P 500 (IVV) – 1,274,000 shares, 41.43% of the total portfolio. Shares added by 114.84%SPDR S&P 500 (SPY) – 1,192,350 shares, 38.52% of the total portfolio. Shares added by 158.64%iShares MSCI EAFE (EFA) – 1,043,001 shares, 8.7% of the total portfolio. Shares added by 12.39%iShares Floating Rate Bond (FLOT) – 1,000,000 shares, 7.33% of the total portfolio. NewStar Financial Inc (NEWS) – 3,000,000 shares, 4.01%

  • [By WWW.GURUFOCUS.COM]

    For the details of SWISS RE LTD’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SWISS+RE+LTD

    These are the top 5 holdings of SWISS RE LTDiShares Core S&P 500 (IVV) – 1,641,300 shares, 34.54% of the total portfolio. Shares added by 6.79%SPDR S&P 500 (SPY) – 1,003,200 shares, 20.97% of the total portfolio. Shares reduced by 34.15%iShares MSCI EAFE (EFA) – 2,800,100 shares, 15.78% of the total portfolio. Shares added by 170.34%iShares 1-3 Year Credit Bond ETF (CSJ) – 1,659,000 shares, 15.1% of the total portfolio. New PositionVanguard Short-Term Corporate Bond ETF (VCSH) – 937,000 shares, 6.48% of the total po

  • [By Todd Shriber, ETF Professor]

    Passive ETFs continuing to top active rivals is not all about the performance of U.S. stocks this year. Yes, the S&P 500 is up 5.5 percent year-to-date, but that is not a jaw-dropping performance. Much of the ongoing out-performance of passive ETFs over active counterparts this year is attributable to fees. Just look at the rock-bottom fees on ETFs such as the SPDR S&P 500 ETF (NYSE: SPY) and the iShares S&P 500 Core ETF (NYSE: IVV).

Leave a Reply

Your email address will not be published. Required fields are marked *